---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-003382"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:52:46.270229+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KalVista reports Q3 net loss $22.5M; KVD900 Phase 3 trial initiated, data expected H2 2023

## Summary
- Net loss of $22.5M ($0.92/share) vs $10.0M loss ($0.56) YoY; R&D spend $19.7M (up from $9.1M).
- Cash and securities $194.8M at Jan 31, 2022, down from $248.9M at Apr 30, 2021.
- Initiated Phase 3 KONFIDENT trial for KVD900 on-demand HAE treatment; data expected H2 2023.
- Phase 2 KOMPLETE trial for KVD824 (prophylaxis) enrolling on track; data expected mid-2023.
- Factor XIIa inhibitor program advancing; first IND anticipated in 2023.

## SEC filing metadata
- accession: 0000950170-22-003382
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/0000950170-22-003382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022003382/kalv-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-003382
- JSON: https://secwatch.observer/filing/0000950170-22-003382.json
- Plain text: https://secwatch.observer/filing/0000950170-22-003382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.